1. Erythropoietin treatment is associated with a reduction in moderate to severe bronchopulmonary dysplasia in preterm infants. A regional retrospective study
   Kim Chi T. Bui et al, 2019, Early Human Development CrossRef
2. Recent advances in our understanding of the mechanisms of lung alveolarization and bronchopulmonary dysplasia
   Ettore Lignelli et al, 2019, American Journal of Physiology-Lung Cellular and Molecular Physiology CrossRef
3. Strategies for the prevention of bronchopulmonary dysplasia
   Gianluca Dini et al, 2024, Frontiers in Pediatrics CrossRef
4. Recent advances in our understanding of the mechanisms of late lung development and bronchopulmonary dysplasia
   David E. Surate Solaligue et al, 2017, American Journal of Physiology-Lung Cellular and Molecular Physiology CrossRef
5. A Systematic Review of Phytochemistry, Pharmacology and Pharmacokinetics on Astragali Radix: Implications for Astragali Radix as a Personalized Medicine
   Zhenzhen Guo et al, 2019, International Journal of Molecular Sciences CrossRef
6. Quercetin attenuates the hyperoxic lung injury in neonatal mice: Implications for Bronchopulmonary dysplasia (BPD)
   Paramahamsa Maturu et al, 2018, Food and Chemical Toxicology CrossRef
7. Pharmacotherapy in Bronchopulmonary Dysplasia: What Is the Evidence?
   Rishika P. Sakaria et al, 2022, Frontiers in Pediatrics CrossRef
8. EGFL7: Master regulator of cancer pathogenesis, angiogenesis and an emerging mediator of bone homeostasis
   Guoju Hong et al, 2018, Journal of Cellular Physiology CrossRef
9. Erythropoietin for preventing bronchopulmonary dysplasia in preterm infants: A systematic review and meta‐analysis
   Jing Li et al, 2022, Pediatric Pulmonology CrossRef